- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01807156
Phase II Trial of Tivozanib in Advanced Hepatocellular Cancer
Study Overview
Detailed Description
Angiogenesis is the formation of new blood vessels. Angiogenesis is driven by cytokines including vascular endothelial growth factor. Tivozanib is an oral medication that inhibits vascular endothelial growth factor preventing tumor from developing new blood vessels.
The purpose of this study is to evaluate the effects of tivozanib on hepatocellular (liver) cancer. Participants in the study take tivozanib daily at a dose of 1 mg for 1month. if doing well the dose would be increased to 1.5 mg per day. Patients are monitored for response using CT or MRI scans every 2months. In addition, patients will have blood draws to evaluate the effects of tivozanib on blood vessels.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University, Winship Cancer Institute
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with measurable, histological diagnosis of hepatocellular carcinoma (HCC) and whose disease is not amenable to surgical or regional therapy.
Prior allowed therapy:
Surgery including hepatic resection
- Minimum of 4 weeks since any surgical procedure.
- Patients must have adequately recovered from surgery.
Regional therapy
- Includes transarterial chemoembolization (TACE), drug-eluting bead [DEB]-TACE, percutaneous ethanol injection, radiofrequency/cryo ablation, Yttrium-90 radioembolization.
- More than 2 weeks must have lapsed from therapy.
- There must be an indicator lesion outside the treated area or clear evidence of progression in the treated lesion, not amenable for further local therapies.
- Concomitant sorafenib with regional therapy is allowed as long as no evidence of progression on sorafenib.
- Prior adjuvant sorafenib is allowed, if completed more than 6 months prior to disease recurrence.
- Adequate hematological, liver and metabolic organ function.
- Signed informed consent.
Exclusion Criteria:
- Patients with mixed histology or fibrolamellar variant.
- Prior systemic therapy for metastatic disease.
- Uncontrolled hypertension (HTN).
- Symptomatic heart failure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Tivozanib
Patients would receive Tivozanib 1.0 mg/day orally, 3 weeks on, one week off, for one cycle starting day 1.
If no adverse event is encountered, patients will continue subsequent cycles of Tivozanib 1.5 mg/day orally; 3 weeks on/1 week off, dosing schedule.
Patients will continue on treatment until disease progression, unacceptable toxicity, or patient withdrawal from the study.
|
Oral medication given daily.
No placebo.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Patients With Advanced Hepatocellular Cancer (HCC) Receiving Tivozanib Who Are Free From Progression
Time Frame: 6 Months
|
Evaluation of disease progression in the patients with advanced hepatocellular cancer (HCC) receiving tivozanib will be made using CT or MRI scan of the organ(s) with the target lesion(s).
Response Evaluation Criteria In Solid Tumors (RECIST) criteria 1.1 will be used for objective tumor response assessment.
Measurable lesions can be measured in at least one dimension as ≥ 20 mm with conventional CT scan techniques or as ≥ 10 mm with spiral CT scan.
Target lesions are all measurable lesions up to a maximum of 5 lesions.
Target lesions are selected for their size and suitability for accurate repetitive measurements.
The sum of the longest diameter of all target lesions will be calculated and reported as the baseline sum longest diameter (LD).
This will be used as a reference to further quantify objective response.
|
6 Months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response Rate Based on Response Evaluation Criteria in Solid Tumors (RECIST) Criteria
Time Frame: 6 months
|
Measurable lesions: Lesions that can be measured in at least one dimension as ≥ 20 mm with conventional CT scan techniques or as ≥ 10 mm with spiral CT scan. Non-measurable lesions: All other lesions including small lesions (longest diameter < 20 mm with conventional techniques) and other non-measurable lesions including: pleural effusions, ascites, and disease documented by indirect evidence (e.g. biochemical abnormalities). Target lesions: All measurable lesions up to a maximum of 5 lesions. Target lesions are selected for their size and suitability for accurate repetitive measurements. The sum of the longest diameter of all target lesions will be calculated and reported as the baseline sum longest diameter (LD). This will be used as a reference to further quantify objective response. Non-target lesions: All other lesions are identified as non-target lesions and should be followed as present or absent. |
6 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB00061422 (Other Identifier: Emory University)
- WINSHIP2302-12 (Other Identifier: Other)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatocellular Cancer
-
Ethicon, Inc.CompletedCarcinoma, Hepatocellular | Hepatocellular Carcinoma | Hepatocellular Cancer | Cancer, HepatocellularKorea, Republic of
-
Omega TherapeuticsRecruitingHepatocellular Carcinoma | Solid Tumor | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Recurrent | Liver, Cancer of, Non-ResectableUnited States, Hong Kong, Korea, Republic of, Singapore, Taiwan
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedAdvanced Adult Hepatocellular Carcinoma | Advanced Adult Primary Liver Cancer | Adult Primary Hepatocellular Carcinoma | BCLC Stage B Adult Hepatocellular Carcinoma | BCLC Stage C Adult Hepatocellular CarcinomaUnited States
-
Lisa H. Butterfield, Ph.D.National Cancer Institute (NCI)TerminatedHepatocellular Carcinoma | Liver Cancer | Cancer of Liver | Hepatoma | Hepatocellular Cancer | Hepatic Cancer | Liver Cell Carcinoma | Cancer, Hepatocellular | Liver Cancer, Adult | Liver Cell Carcinoma, Adult | Cancer of the Liver | Neoplasms, Liver | Hepatic Neoplasms | Neoplasms, HepaticUnited States
-
Asan Medical CenterSeoul National University Hospital; Hanyang University; Soon Chun Hyang UniversityRecruitingHepatocellular Carcinoma | Liver Cancer | Hepatocellular Carcinoma Non-resectable | Hepatocellular Cancer | Hepatocellular Carcinoma Stage IVKorea, Republic of
-
Allison O'Neill, MDRecruitingLiver Cancer | Fibrolamellar Carcinoma | Hepatocellular Carcinoma, Childhood | Liver Cancer, PediatricUnited States
-
Medical College of WisconsinWithdrawnHepatocellular Carcinoma | Liver Cancer | Hepatoma | Hepatocellular CancerUnited States
-
Daiichi Sankyo, Inc.TerminatedAdvanced Solid Tumors | Hepatocellular Cancer (HCC)United Kingdom
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityRecruitingStage III Hepatocellular Cancer (CNLC Staging)China
-
Henan Cancer HospitalNot yet recruiting
Clinical Trials on Tivozanib
-
Dana-Farber Cancer InstituteNational Comprehensive Cancer Network; AVEO Pharmaceuticals, Inc.TerminatedOvarian Cancer | Fallopian Tube Cancer | Primary Peritoneal CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer Network; AVEO...CompletedAdvanced Adult Hepatocellular Carcinoma | Non-Resectable Hepatocellular CarcinomaUnited States
-
AVEO Pharmaceuticals, Inc.Completed
-
AVEO Pharmaceuticals, Inc.CompletedRenal Cell CarcinomaUnited States, Canada
-
AVEO Pharmaceuticals, Inc.CompletedHepatic ImpairmentUnited States
-
Massachusetts General HospitalNational Comprehensive Cancer NetworkCompleted
-
AVEO Pharmaceuticals, Inc.CompletedFood Effect of Tivozanib in Health SubjectsUnited States
-
AVEO Pharmaceuticals, Inc.CompletedCarcinoma, Non-Small-Cell LungUnited States
-
AVEO Pharmaceuticals, Inc.CompletedColorectal Cancer | Gastrointestinal CancerNetherlands
-
AVEO Pharmaceuticals, Inc.CompletedCarcinoma, Renal CellUnited States, Hungary, Spain, United Kingdom, Italy, Germany, France, Belgium, Czechia, Canada, Denmark, Poland